Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1,851.50    31.00 (1.70%)
Bid:
1,851.50
Ask:
1,852.00
Spread: 0.50 (0.027%)
Market Cap: £74.25b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Result of AGM

7 May 2025 18:22

RNS Number : 7755H
GSK PLC
07 May 2025
 

GSK plc

 

Results of 25th Annual General Meeting

 

GSK plc ('GSK') held a hybrid Annual General Meeting ('AGM') at 2.30pm on Wednesday 7 May 2025 at The Landmark London, 222 Marylebone Road, London, NW1 6JQ. Shareholders were able to join the meeting in person or virtually via the Lumi AGM website and Zoom.

 

All valid proxy votes (whether submitted electronically or in hard copy form) were included in the poll taken at the meeting.

 

All 25 resolutions were passed and decided upon by a poll. The table below shows the results for each resolution. The full text of the resolutions is contained in the Notice of AGM published on 24 March 2025, which is available on GSK's website at www.gsk.com.

 

Resolution

Total votes for(1)(2)

%

Total votes against(2)

%

Total votes cast

% of Issued Share Capital voted(3)

Votes withheld(4)

1

Receive and adopt the 2024 Annual Report

3,031,647,740

99.82

5,472,209

0.18

3,037,119,949

73.91%

12,204,390

2

Approve the Annual report on remuneration 

2,810,183,626

92.46

229,176,108

7.54

3,039,359,734

73.97%

9,979,421

3

Approve the Remuneration policy

2,786,567,742

93.10

206,384,696

6.90

2,992,952,438

72.84%

56,376,703

4

Election of Dr Gavin Screaton

3,040,206,238

99.89

3,385,136

0.11

3,043,591,374

74.07%

5,719,426

5

Re-election of Sir Jonathan Symonds

2,947,917,394

98.40

48,075,530

1.60

2,995,992,924

72.91%

53,319,043

6

Re-election of Dame Emma Walmsley

3,038,248,728

99.82

5,613,533

0.18

3,043,862,261

74.08%

5,444,311

7

Re-election of Julie Brown

3,034,344,765

99.69

9,515,889

0.31

3,043,860,654

74.08%

5,460,463

8

Re-election of Elizabeth McKee Anderson

2,941,679,748

96.64

102,161,424

3.36

3,043,841,172

74.08%

5,465,676

9

Re-election of Charles Bancroft

2,956,308,387

97.13

87,450,752

2.87

3,043,759,139

74.07%

5,553,709

10

Re-election of Dr Hal Barron

3,039,339,475

99.85

4,466,176

0.15

3,043,805,651

74.08%

5,489,801

11

Re-election of Dr Anne Beal

2,955,431,838

97.09

88,492,673

2.91

3,043,924,511

74.08%

5,388,566

12

Re-election of Wendy Becker

2,933,164,994

96.36

110,745,350

3.64

3,043,910,344

74.08%

5,400,009

13

Re-election of Dr Harry C Dietz

3,039,383,688

99.86

4,369,000

0.14

3,043,752,688

74.07%

5,560,851

14

Re-election of Dr Jeannie Lee

3,039,577,387

99.86

4,161,377

0.14

3,043,738,764

74.07%

5,574,652

15

Re-election of Dr Vishal Sikka

3,038,858,707

99.84

4,756,490

0.16

3,043,615,197

74.07%

5,688,803

16

Re-appointment of the auditor

3,025,673,462

99.89

3,223,574

0.11

3,028,897,036

73.71%

20,430,064

17

Remuneration of the auditor

3,039,931,435

99.88

3,782,302

0.12

3,043,713,737

74.07%

5,591,584

18

Authority for the company to make donations to political organisations and incur political expenditure

2,946,755,927

99.01

29,581,561

0.99

2,976,337,488

72.43%

72,977,673

19

Authority to allot shares

2,899,903,495

95.30

143,133,156

4.70

3,043,036,651

74.06%

6,282,441

20

Disapplication of pre-emption rights - general power(5)

2,941,521,597

96.72

99,811,731

3.28

3,041,333,328

74.02%

7,942,085

21

Disapplication of pre-emption rights - in connection with an acquisition or specified capital investment(5)

2,962,038,875

97.39

79,351,038

2.61

3,041,389,913

74.02%

7,904,048

22

Authority for the company to purchase its own shares(5)

3,036,538,826

99.83

5,280,936

0.17

3,041,819,762

74.03%

7,499,989

23

Exemption from statement of senior statutory auditor's name

3,022,840,749

99.74

7,951,051

0.26

3,030,791,800

73.76%

18,502,136

24

Authority for reduced notice of a general meeting other than an AGM(5)

2,863,892,275

94.11

179,242,127

5.89

3,043,134,402

74.06%

6,172,307

25

Approve the adoption of the GSK Share Value Plan

2,972,805,515

99.56

13,033,137

0.44

2,985,838,652

72.67%

63,503,752

 

 

Notes:

 

(1) The "for" votes include those giving the Chair discretion.

(2) Votes "for" and "against" are expressed as a percentage of the total votes cast.

(3) The Company's issued share capital as at 2 May 2025 consisted of 4,109,037,095 shares of 31 ¼ pence each ('Ordinary Shares') excluding Ordinary Shares held in Treasury. Every shareholder has one vote for every Ordinary Share held.

(4) A "vote withheld" is not a vote in law and is not counted in the calculation of the proportion of votes "for" or "against" a resolution.

(5) Indicates Special Resolutions requiring a 75% majority of votes cast.

 

 

The following table provides further information on participation in the AGM:

 

 

GSK's 25th AGM

(Hybrid meeting)

(2025)

GSK's 24th AGM

(Hybrid meeting)

(2024)

Issued share capital (excluding Treasury Shares)

4,109,037,095

 

4,314,108,510

Total votes cast and votes withheld lodged as a % of GSK's issued share capital (excluding Treasury Shares)

74.21%

73.11%

Total shareholder population

86,241

60,448

Total number of proxies lodged

3,743

2,886

Number of shareholders in attendance

130 in person

25 participated virtually

125 in person

38 participated virtually

% of shareholders who lodged proxies

4.34%

4.77%

 

 

The above poll results will shortly be available on the company's website at www.gsk.com.

 

In accordance with Listing Rule 6.4.2 of the Financial Conduct Authority's (FCA) Listing Rules, a copy of the resolutions, other than those concerning ordinary business, will be submitted to the FCA and will, in due course, be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism

 

 

V A Whyte

Company Secretary

7 May 2025

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGARMRTMTTMBBA
Date   Source Headline
12th Jun 202511:00 amPRNDirector/PDMR Shareholding
12th Jun 20257:00 amRNSTransaction in Own Shares
11th Jun 20253:30 pmRNSDirector/PDMR Shareholding
11th Jun 20257:00 amRNSTransaction in Own Shares
10th Jun 20257:00 amRNSTransaction in Own Shares
9th Jun 20257:00 amRNSTransaction in Own Shares
6th Jun 20257:00 amRNSTransaction in Own Shares
5th Jun 20257:00 amRNSTransaction in Own Shares
4th Jun 20257:00 amRNSGSK - second tranche of share buyback programme
4th Jun 20257:00 amRNSTransaction in Own Shares
3rd Jun 20257:00 amRNSTransaction in Own Shares
2nd Jun 20253:30 pmRNSDirector/PDMR Shareholding
2nd Jun 20253:00 pmRNSTotal Voting Rights
2nd Jun 20257:00 amRNSLinerixibat file accepted for review by US FDA
2nd Jun 20257:00 amRNSTransaction in Own Shares
30th May 20257:00 amRNSTransaction in Own Shares
29th May 20257:00 amRNSTransaction in Own Shares
28th May 202512:00 pmRNSGSK stops Phase 3 trial on cUTIs for efficacy
28th May 20257:00 amRNSTransaction in Own Shares
27th May 20257:00 amRNSTransaction in Own Shares
23rd May 202512:16 pmRNSpositive CHMP opinion on Blenrep in EU
23rd May 20257:00 amRNSFDA approves Nucala COPD indication
23rd May 20257:00 amRNSTransaction in Own Shares
22nd May 20257:00 amRNSTransaction in Own Shares
21st May 20257:00 amRNSTransaction in Own Shares
20th May 20253:30 pmRNSDirector/PDMR Shareholding
20th May 20257:00 amRNSTransaction in Own Shares
19th May 20257:00 amRNSBlenrep for 2L+ multiple myeloma approved in Japan
19th May 20257:00 amRNSTransaction in Own Shares
16th May 20257:00 amRNSTransaction in Own Shares
15th May 20257:00 amRNSTransaction in Own Shares
14th May 20257:00 amRNSGSK to acquire efimosfermin
14th May 20257:00 amRNSTransaction in Own Shares
13th May 20253:30 pmRNSDirector/PDMR Shareholding
13th May 202512:56 pmRNSUpdate on belrestotug development programme
13th May 20257:00 amRNSTransaction in Own Shares
12th May 20253:31 pmRNSBlock listing Interim Review
12th May 20257:00 amRNSTransaction in Own Shares
9th May 20257:00 amRNSTransaction in Own Shares
8th May 20255:15 pmRNSDirector/PDMR Shareholding
8th May 20253:30 pmRNSDirector/PDMR Shareholding
8th May 202511:15 amRNSLinerixibat GLISTEN pIII trial data at EASL
8th May 20257:00 amRNSTransaction in Own Shares
7th May 20256:22 pmRNSResult of AGM
7th May 20257:00 amRNSTransaction in Own Shares
6th May 20257:00 amRNSTransaction in Own Shares
2nd May 20257:00 amRNSTransaction in Own Shares
1st May 20253:30 pmRNSDirector/PDMR Shareholding
1st May 20253:00 pmRNSTotal Voting Rights
1st May 20257:00 amRNSNucala MATINEE data in COPD published in NEJM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.